CompanionDx Launches NGS-based Cancer Assays Using GenomOncology's GO Clinical Workbench

HOUSTON and CLEVELAND, Nov. 5, 2014 /PRNewswire/ -- CompanionDx Reference Lab, LLC, a high-complexity CLIA-certified laboratory specializing in pharmacogenomics, cancer companion diagnostics and targeted next-generation sequencing (NGS), announced today it is offering a series of NGS-based assays related to cancer. To enable efficient and compliant clinical reporting from NGS, CompanionDx chose to partner with GenomOncology, an Ohio-based genomics technology and services provider.

"The ability to deliver therapy-driven clinical reports—rapidly and in a high-assurance manner—was an important requirement in our evaluation process," David Lasecki, president of CompanionDx, states.  "In addition, the Go Clinical Workbench enables our laboratory to manage increased volume and quickly add new assays to meet the needs of our oncologists."

Utilizing GenomOncology's GO Clinical Workbench, CompanionDx is able to deliver customized clinical reports to enable oncologists to guide therapy based on a patient's tumor genotype.

"Creating high-quality, reproducible data from NGS has become easier," states Steve Gustafson, chief operating officer of GenomOncology. "However, the reporting process in the clinical laboratory poses several challenges. Our primary focus is optimizing this process from QC to clinical interpretation, sign out and delivery."

CompanionDx has a strong history of innovation related to personalized medicine," Lasecki said. "Launching these NGS-based cancer tests is a natural progression in our strategy to enable physicians to provide better care for their patients."

About CompanionDx Reference Lab, LLC

CompanionDx, a leading advanced specialty diagnostics company, is committed to providing accurate, timely and practical information to physicians through DNA testing in its CLIA-certified labs and intuitive, actionable reports. The staff of clinicians assesses the test results and offers treatment recommendations which help physicians make more informed decisions and provide significant value to patients by improving outcomes, reducing severe adverse drug reactions and reducing costs associated with ineffective therapy. For more information, visit www.companiondxlab.com.

About GenomOncology

GenomOncology is enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. In collaboration with molecular pathologists and physicians, GenomOncology has developed the GO Clinical Workbench™, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the specific molecular profile of each patient's tumor genome into an actionable clinical report. GenomOncology's research platform, GenomAnalytics™, allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants, reducing the time required to understand the genomic alterations that lead to new discoveries about the biology of cancer. More information can be found on the company's website at www.genomoncology.com.

Logo - http://photos.prnewswire.com/prnh/20140204/CL58248LOGO 

SOURCE GenomOncology